Cambridge Antibody Technology cambridgeantibody.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Cambridge Antibody Technology is engaged in the development of human monoclonal antibodies as new treatments for disease, having developed a pipeline of human monoclonal antibodies. HUMIRA, an antibody for the treatment of rheumatoid arthritis, developed in collaboration with Abbott, is on the market. Cambridge Antibody Technology was acquired by AstraZeneca for cash in 2006.

Cambridge Antibody Technology is engaged in the development of human monoclonal antibodies as new treatments for disease, having developed a pipeline of human monoclonal antibodies. HUMIRA, an antibody for the treatment of rheumatoid arthritis, devel...Show all

Company (Acquired)

Phone:

Fax:




United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Cambridge Antibody Technology $0M May 15, 2006
See all 18 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Cambridge Antibody Technology Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 18 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Antibodies against human or mouse il-21 receptor Mar 12, 2004 Feb 24, 2009 Patent